[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"f399d23b-7387-4d29-af04-b8eeed6c99e9","acronym":"Maverick","url":"https://clinicaltrials.gov/study/NCT05361915","created_at":"2022-05-05T16:54:04.575Z","updated_at":"2024-07-02T16:35:14.341Z","phase":"Phase 2","brief_title":"Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT05361915 - Maverick","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" HSD3B1","pipe":"","alterations":" ","tags":["HSD3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Fujovee (abivertinib)"],"overall_status":"Suspended","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-03-18"},{"id":"3b34d54f-654b-4f1c-81d4-bdb04f223c27","acronym":"","url":"https://clinicaltrials.gov/study/NCT02330367","created_at":"2021-01-18T11:03:27.813Z","updated_at":"2024-07-02T16:36:24.587Z","phase":"Phase 1/2","brief_title":"Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC","source_id_and_acronym":"NCT02330367","lead_sponsor":"Hangzhou ACEA Pharmaceutical Research Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fujovee (abivertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 368","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2021-09-10"},{"id":"af454ec7-56dc-42db-b71d-11d65124b887","acronym":"","url":"https://clinicaltrials.gov/study/NCT03856697","created_at":"2021-01-18T19:01:54.903Z","updated_at":"2024-07-02T16:37:02.388Z","phase":"Phase 3","brief_title":"Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation","source_id_and_acronym":"NCT03856697","lead_sponsor":"Hangzhou ACEA Pharmaceutical Research Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • Fujovee (abivertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 406","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2019-02-27"},{"id":"6f4b5513-cf9f-420d-9be4-2298be6b2701","acronym":"","url":"https://clinicaltrials.gov/study/NCT03300115","created_at":"2021-01-18T16:18:11.616Z","updated_at":"2024-07-02T16:37:02.662Z","phase":"Phase 2","brief_title":"Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC","source_id_and_acronym":"NCT03300115","lead_sponsor":"Hangzhou ACEA Pharmaceutical Research Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fujovee (abivertinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 222","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/17/2019","primary_completion_date":" 06/17/2019","study_txt":" Completion: 12/17/2020","study_completion_date":" 12/17/2020","last_update_posted":"2019-02-19"},{"id":"c5c3f118-9c03-4425-9f17-6077a7ad61b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03058094","created_at":"2021-01-18T15:03:44.024Z","updated_at":"2024-07-02T16:37:03.231Z","phase":"Phase 3","brief_title":"A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI","source_id_and_acronym":"NCT03058094","lead_sponsor":"Hangzhou ACEA Pharmaceutical Research Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • Fujovee (abivertinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2019-02-04"},{"id":"869c9172-9ad4-453e-aad9-d6a0be2b2332","acronym":"","url":"https://clinicaltrials.gov/study/NCT03053219","created_at":"2021-01-18T15:02:15.076Z","updated_at":"2025-02-25T13:34:53.143Z","phase":"Phase 1","brief_title":"Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment","source_id_and_acronym":"NCT03053219","lead_sponsor":"Hangzhou ACEA Pharmaceutical Research Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fujovee (abivertinib)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2019-02-01"}]